Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

CAREPATH · Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health

HORIZONStatus: SIGNED1 May 202530 April 2030EU funding €11,300,000Call HORIZON-JU-IHI-2024-06-two-stage

CAREPATH aims to improve chronic disease management and medication persistence by transforming the care ecosystem, ensuring personalised support for better health outcomes, and reducing healthcare costs. We focus on improving medication adherence and persistence for three prevalent chronic conditions: Obesity (BMI ≥ 30 kg/m2), Type 2 Diabetes Mellitus (T2DM), and cardiovascular diseases (CVD), including chronic heart failure (CHF), across six diverse European countries: Germany, Israel, the Netherlands, Poland, Spain, and Sweden. These countries represent various EU healthcare environments and economic statuses, emphasising the need for tailored approaches to patient care.Our strategy involves integrating localised non-digital and digital health solutions to address the unique healthcare delivery challenges in each region. The CAREPATH toolbox collects, combines, and customises existing solutions into adaptable modules for broad application in both primary and secondary care settings. This toolbox will be tested in four studies across two settings in all six countries in both primary and secondary care. Three pilot studies in different regions as well as a proof-of-concept study in Germany will be conducted. This comprehensive evaluation, including HTA, aims to assess the toolbox's implementation and effectiveness, with a strong focus on learning what works for what groups of patients in which setting.Recognizing the significant impact of obesity, particular emphasis is placed on treatment adherence and persistence of medications that facilitate weight loss, such as dual GIP/GLP-1 receptor agonists, but CAREPATH studies also include patients using lipid-lowering drugs, insulin, and SGLT2 inhibitors. Our goal is to empower patients by improving communication and data sharing among patients, healthcare providers, and other stakeholders, thereby supporting the entire ecosystem and alleviating the burden on healthcare systems.

Consortium · 46 organisations

coordinator

RISE RESEARCH INSTITUTES OF SWEDEN AB

SE · €700,661

participant

BIOCORP PRODUCTION

FR

associatedPartner

PFIZER LIMITED

UK

associatedPartner

Lilly Deutschland GmbH

DE

participant

INSTITUT CATALA DE LA SALUT

ES · €260,843

participant

MAMA PRODUCTIES BV

NL · €299,063

participant

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

DE · €220,095

participant

Imagine AI B.V.

NL · €45,000

participant

STICHTING VU

NL · €493,750

participant

HL7 EUROPE

BE · €409,250

participant

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

DE · €492,500

associatedPartner

A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE SRL

IT

associatedPartner

Lilly France

FR

thirdParty

FUNDACIO INSTITUT UNIVERSITARI PERA LA RECERCA A L'ATENCIO PRIMARIA DE SALUT JORDI GOL I GURINA

ES

participant

ACADEMISCH ZIEKENHUIS GRONINGEN

NL · €749,596

participant

Ogolnopolskie Stowarzyszenie Pacjentow ze Schorzeniami Serca i Naczyn Ecoserce

PL · €25,000

participant

Thaumatec SP ZOO

PL · €247,500

participant

LANDSCHAFTSVERBAND RHEINLAND

DE · €164,625

participant

FUNDACIO INSTITUT D'INVESTIGACIO SANITARIA ILLES BALEARS

ES · €340,066

associatedPartner

MENARINI BENELUX

BE

participant

Asociación Bariátrica Híspalis Nacional

ES · €25,000

participant

UNIVERSITAET LEIPZIG

DE · €162,500

associatedPartner

SERVIER AFFAIRES MEDICALES

FR

participant

Riksforbundet HjartLung

SE · €25,000

thirdParty

INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL

ES

participant

BAR ILAN UNIVERSITY

IL · €593,151

participant

WAVY ASSISTANT BV

NL · €2,457,000

participant

STICHTING AMSTERDAM UMC

NL · €1,299,531

participant

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

DE · €486,660

participant

VASTRA GOTALANDSREGIONEN

SE · €338,625

participant

ISRAEL DIABETES ASSOCIATION

IL

participant

MENARINI RICERCHE SPA

IT

participant

THE EUROPEAN COALITION FOR PEOPLE LIVING WITH OBESITY COMPANY LIMITED BY GUARANTEE

IE · €224,000

associatedPartner

SERVIER INTERNATIONAL

FR

participant

ABBOTT GMBH

DE

participant

PFIZER INC

US

participant

UNIWERSYTET MEDYCZNY W LODZI

PL · €383,725

participant

RIJKSUNIVERSITEIT GRONINGEN

NL · €531,859

associatedPartner

Pfizer SLU

ES

participant

EBERHARD KARLS UNIVERSITAET TUEBINGEN

DE · €162,500

participant

NOVO NORDISK A/S

DK

participant

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

FR

participant

ELI LILLY AND COMPANY

US

participant

IQVIA AG

CH

associatedPartner

Pfizer R&D UK Limited

UK

participant

TECHNISCHE UNIVERSITAET DRESDEN

DE · €162,500

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.